Protein-Based Drug Carrier Specific for Her2-Positive Breast Cancer Cells

Protein-Based Drug Carrier Specific for Her2-Positive Breast Cancer Cells Publisher

Jamallivani N¹ ; Mohammadian E¹ ; Sheikh Arabi M^{1, 2} ; Safdari Y^{2, 3}

Show Affiliations

1. Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran
2. Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran
3. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran

Source: Journal of Drug Delivery Science and Technology Published:2020

Abstract

The aim of this study was to design a protein-based single chain vehicle that be able to recognize and enter HER2-overexpressing cancer cells and subsequently enter their nuclei. To this end, we conjugated VH domain of an anti-HER2 antibody (Herceptin) as HER2 targeting element, nine arginine residues (summarily called 9R) as cell penetrating peptide (CPP), and nuclear localization signals (NLSs) of TUS and c-Myc proteins as nuclear delivery mediators. The recombinant construct was labeled with FITC fluorescent dye to trace within the cells. Fluorescent imaging revealed that the construct was able to specifically recognize HER2-overexpressing cells and enter their nuclei. © 2020 Elsevier B.V.

Experts (# of related papers)

Mohammad Hossein Ghahremani (1)

Kobra Omidfar (1)

Style	Citing Format
MLA	Jamallivani N, et al.. "Protein-Based Drug Carrier Specific for Her2-Positive Breast Cancer Cells." Journal of Drug Delivery Science and Technology, vol. 57, no. , 2020, pp. -.
APA	Jamallivani N, Mohammadian E, Sheikh Arabi M, Safdari Y (2020). Protein-Based Drug Carrier Specific for Her2-Positive Breast Cancer Cells. Journal of Drug Delivery Science and Technology, 57(), -.
Chicago	Jamallivani N, Mohammadian E, Sheikh Arabi M, Safdari Y. "Protein-Based Drug Carrier Specific for Her2-Positive Breast Cancer Cells." Journal of Drug Delivery Science and Technology 57, no. (2020): -.
Harvard	Jamallivani N et al. (2020) 'Protein-Based Drug Carrier Specific for Her2-Positive Breast Cancer Cells', Journal of Drug Delivery Science and Technology, 57(), pp. -.
Vancouver	Jamallivani N, Mohammadian E, Sheikh Arabi M, Safdari Y. Protein-Based Drug Carrier Specific for Her2-Positive Breast Cancer Cells. Journal of Drug Delivery Science and Technology. 2020;57():-.
BibTex	@article{ author = {Jamallivani N and Mohammadian E and Sheikh Arabi M and Safdari Y}, title = {Protein-Based Drug Carrier Specific for Her2-Positive Breast Cancer Cells}, journal = {Journal of Drug Delivery Science and Technology}, volume = {57}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Jamallivani N AU - Mohammadian E AU - Sheikh Arabi M AU - Safdari Y TI - Protein-Based Drug Carrier Specific for Her2-Positive Breast Cancer Cells JO - Journal of Drug Delivery Science and Technology VL - 57 IS - SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract